JP2011503207A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503207A5
JP2011503207A5 JP2010534249A JP2010534249A JP2011503207A5 JP 2011503207 A5 JP2011503207 A5 JP 2011503207A5 JP 2010534249 A JP2010534249 A JP 2010534249A JP 2010534249 A JP2010534249 A JP 2010534249A JP 2011503207 A5 JP2011503207 A5 JP 2011503207A5
Authority
JP
Japan
Prior art keywords
promoter
cell
pim
cells
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/083693 external-priority patent/WO2009065080A1/en
Publication of JP2011503207A publication Critical patent/JP2011503207A/ja
Publication of JP2011503207A5 publication Critical patent/JP2011503207A5/ja
Pending legal-status Critical Current

Links

JP2010534249A 2007-11-16 2008-11-14 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 Pending JP2011503207A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98875307P 2007-11-16 2007-11-16
US9169808P 2008-08-25 2008-08-25
PCT/US2008/083693 WO2009065080A1 (en) 2007-11-16 2008-11-14 Compositions and method for manipulating pim-1 activity in circulatory system cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014154915A Division JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2011503207A JP2011503207A (ja) 2011-01-27
JP2011503207A5 true JP2011503207A5 (enExample) 2012-01-05

Family

ID=40639186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534249A Pending JP2011503207A (ja) 2007-11-16 2008-11-14 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
JP2014154915A Expired - Fee Related JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014154915A Expired - Fee Related JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Country Status (5)

Country Link
US (5) US8617534B2 (enExample)
EP (1) EP2209889B1 (enExample)
JP (2) JP2011503207A (enExample)
CA (1) CA2705862C (enExample)
WO (1) WO2009065080A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP2020524002A (ja) 2017-06-16 2020-08-13 エイブリィ セラピューティクス インコーポレイテッド 三次元組織組成物及び使用方法
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108913655B (zh) * 2018-07-16 2022-07-15 浙江大学 基于多能干细胞技术建立“人源性”心肌肥大模型的方法
WO2020081604A2 (en) * 2018-10-15 2020-04-23 Avery Therapeutics, Inc. Cell-free compositions and methods for restoration or enhancement of tissue function
MX2022009883A (es) 2020-02-13 2022-10-03 Tenaya Therapeutics Inc Vectores de genoterapia para tratar enfermedades cardíacas.
US20230282387A1 (en) * 2020-09-04 2023-09-07 Dexerials Corporation Conductive layered product, optical device using same, and manufacturing method for conductive layered product

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
WO1998010085A2 (en) * 1996-09-05 1998-03-12 The Regents Of The University Of California Gene therapy for congestive heart failure
US20040132190A1 (en) 1995-02-28 2004-07-08 The Regents Of The University Of California Gene therapy for myocardial ischemia
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
GB2325003B (en) 1996-10-17 2000-05-10 Oxford Biomedica Ltd Rectroviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP0981636B1 (en) 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
EP1005327A1 (en) 1997-07-02 2000-06-07 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
ATE528405T1 (de) 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6867348B1 (en) * 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20020172663A1 (en) * 2001-01-23 2002-11-21 Maria Palasis Localized myocardial injection method for treating ischemic myocardium
US20030003582A1 (en) 2001-05-08 2003-01-02 Tranzyme, Inc. Trans-viral vector mediated gene transfer to the retina
US7732199B2 (en) * 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
CA2505251A1 (en) * 2002-11-05 2004-05-27 Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
CN100567502C (zh) * 2003-04-03 2009-12-09 株式会社康福来 药学制剂
EP1642903A4 (en) * 2003-06-24 2007-03-07 Univ Keio PEPTIDES WITH APOPTOSIS-INHIBITING EFFECT
US7135339B2 (en) 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2005060935A1 (ja) 2003-12-24 2005-07-07 Ltt Bio-Pharma Co., Ltd. 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
AU2005219413A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
US20070082042A1 (en) 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
US20080267921A1 (en) * 2004-11-08 2008-10-30 Johns Hopkins University Cardiac Stem Cells
WO2006125321A1 (en) * 2005-05-27 2006-11-30 The Hospital For Sick Children Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
CN103989633A (zh) 2005-07-27 2014-08-20 普洛体维生物治疗公司 制造脂质体的系统和方法
WO2010135401A2 (en) * 2009-05-19 2010-11-25 San Diego State University Foundation Kinase-mediated cytoprotection and enhanced cellular engraftment and persistence

Similar Documents

Publication Publication Date Title
ES2401608T3 (es) Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes
Bhang et al. Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells
US20150139952A1 (en) Methods, compositions, cells, and kits for treating ischemic injury
US10174287B2 (en) Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof
JP7854579B1 (ja) 心臓修復のための不死化心筋幹細胞
US8617534B2 (en) Compositions and method for manipulating PIM-1 activity in circulatory system cells
Cao et al. Combined hypoxia inducible factor-1α and homogeneous endothelial progenitor cell therapy attenuates shunt flow–induced pulmonary arterial hypertension in rabbits
Zakirova et al. Use of biologically active 3D matrix for extensive skin defect treatment in veterinary practice: Case report
US20210113662A1 (en) Compositions and methods for the treatment of ischemia and cardiomyopathy
CA2578815A1 (en) Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
Feng et al. Recent concepts for the roles of progenitor/stem cell niche in heart repair
WO2022196714A1 (ja) 塩基性繊維芽細胞増殖因子（ｂＦＧＦ）遺伝子が導入されたペリサイト
Turner et al. Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart
Lou Human Pluripotent Stem Cells and Patches Enhance the Repairing Efficacy of Infarcted Cardiac Muscle in Mouse Model
Lou Tissue Engineered Cardiac Muscle Patches with Human Pluripotent Stem Cells Enhance the Repairing Efficacy of Infarcted Cardiac Muscle in Mouse Model
Arsenteva et al. STEM CELLS APPLICATION TO ENHANCE THE MYOCARDIAL REGENERATION
Lara-Pezzi et al. Genetic enhancement of cardiac regeneration
CA2897188A1 (en) Cd34 stem cell-related methods and compositions
Papanikolaou et al. Novel Therapies for Heart Failure: The Gene and Cell Methods
Lai et al. Angiomyogenesis for Myocardial repair
Sepúlveda Hypoxia-inducible factor 1 alpha contributes to cardiac healing in mesenchymal stem cells mediated cardiac repair
김미정 Comparison of Viability and Antioxidant Capacity after Freeze-Thawing Between Canine Adipose-Derived Mesenchymal Stem Cells and Heme Oxygenase-1-Overexpressed Cells
Bruckner et al. 160: Human Cord Blood Derived Stem Cells Improve Left Ventricular Function and High Energy Phosphates in a Porcine Model of Myocardial Infarction